Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
D. Bagnasco (GENOVA (GE), Italy), A. Riccio (GENOVA (GE), Italy), L. De Ferrari (GENOVA (GE), Italy), A. Massolo (Pisa, Italy), M. Caminati (Verona, Italy), A. Manfredi (GENOVA, Italy), G. Senna (Verona, Italy), G. Passalacqua (GENOVA, Italy). Serum Amphiregulin expression in severe asthma patients treated with anti-IL-5 therapy. 2262

Member's Comments

No comment yet.

Related content which might interest you: Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Monitoring free serum IgE in severe asthma patients treated with omalizumab Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Increase in systemic IL-5 is associated with mepolizumab treatment failure in patients with severe asthma Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Evolution of patients with severe asthma treated with mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Serum levels of IL-6 in adult patients with moderate to severe asthma. Source: International Congress 2017 – Novel mechanisms in asthma Year: 2017 Monitoring free serum IgE in asthma patients treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Serum eosinophil cationic protein as a potential biomarker for interleukin-5 antibody treatment in patients with severe uncontrolled eosinophilic asthma Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Omalizumab, a recombinant humanized monoclonal anti-IgE antibody, decreases the risk of serious asthma exacerbations requiring hospitalization in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation Source: Eur Respir J 2005; 26: Suppl. 49, 284s Year: 2005 Expression of interleukin-4 receptor in bronchial asthma patients treated with specific immunotherapy (SIT) Source: Eur Respir J 2002; 20: Suppl. 38, 589s Year: 2002 Serum Interleukin (IL)-6 levels in patients with severe asthma disease is associated with blood eosinophilia Source: Virtual Congress 2020 – Clinical characteristics and diagnostic tools for phenotyping asthma and COPD Year: 2020 Serum level of soluble interleukin-2 receptors (sIL-2R) during acute asthma exacerbation, and its relation to severity and response to bronchodilator therapy Source: Eur Respir J 2002; 20: Suppl. 38, 141s Year: 2002 Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Effect of anti-IL-17 biologics on KL-6 level and coexisting interstitial pneumoniain patients with psoriasis Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Salmeterol treatment improves corticosteroid responsivness in patients with corticosteroid-insensitive severe asthma Source: Annual Congress 2005 - Improving asthma control in the harder-to-reach population Year: 2005 Serum TNF-a, IL-12 and IL-13 levels in severe bronchial asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 353s Year: 2004 Serum leptin levels in asthmatic children treated with inhaled corticosteroid Source: Eur Respir J 2004; 24: Suppl. 48, 580s Year: 2004 Change of lung function in severe eosinophilic asthma undergoing treatment with anti-interleukin-5 monoclonal antibody Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Free serum IL-18 levels and responsiveness to omalizumab in patients with severe asthma Source: International Congress 2016 – Asthma: mechanisms and biomarkers that promote clinical understanding Year: 2016